报告题目：Discovery and development of therapeutic proteins using computational protein design and innovation high-throughput screening technologies

报告人：

Yongliang Fang, Ph.D. Co-Founder and Chief Operating Officer at Occulo Bio LLC.

报告时间：2019年5月20日10:00am

报告地点：工程楼B506室

报告人简历：

Dr. Fang received his Ph.D. degree in Bioengineering under the supervision of Prof. Karl Griswold from the Thayer School of Engineering at Dartmouth College. He received his B.E. degree from China Pharmaceutical University. His research in the area of biomolecular engineering has focused on the design and application of high-throughput functional screens for recombinant protein libraries and the deimmunization of therapeutic proteins via computational protein design approach. In 2017, Dr. Fang co-founded Occulo Bio LLC with Prof. Karl Griswold and Prof. Chris Bailey-Kellogg, which has developed proprietary biotherapeutic design and deimmunization platforms and advanced programs with numerous biopharma partners.